Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
10 Setting up camp Shelters That Offer Both Excellence and Isolation - 2Why home maintenance deserves a spot in the annual health and budget plans
- 3The Leonid meteor shower is peaking early this week. Here’s what to know
- 4More parents refusing this shot that prevents serious bleeding at birth
- 5Burger King launches 'SpongeBob' menu ahead of film's release. A look at the Bikini Bottom-inspired meal, plus what taste testers are saying.
- Building an Individual Brand: Illustrations from Forces to be reckoned with
- Find the Abilities Required for Advanced Advertising Position
- Make your choice for the bird that catches your heart!
- A Time of Careful Eating: Individual Tests in Nourishment
- Lucrative Positions in the Advancing Position Market of 2024
- What to know about the hepatitis B shot — and why Trump officials are targeting it
- Instructions to Pick the Best Album Rates for Your Investment funds
- Winter storm warnings issued across Northeast as up to 9 inches of snow forecast; deadly atmospheric river in California snarls travel
- Instructions to Help a Friend or family member Determined to have Cellular breakdown in the lungs
